title: Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels.
abstract: OBJECTIVE
  Blood coagulation abnormalities are common in patients with cancer, particularly after treatment with chemotherapeutic agents. Chemotherapy has been associated with an increased incidence of thromboembolic events, and patients treated with chemotherapy often develop evidence of local phlebitis, which may lead to loss of venous access. We have utilized the radioimmunoassay for plasma fibrinopeptide A (FPA) and in vitro FPA generation to assess the rate of in vivo blood coagulation and the level of plasma thrombin activity in 16 cancer patients treated with chemotherapy. Eight patients were treated twice, once with chemotherapy alone and once with chemotherapy after an intravenous infusion of heparin (5,000 U).
  
  
  RESULTS
  Our results confirm that FPA levels are elevated in most cancer patients. Following chemotherapy, FPA levels were further increased within 45 minutes (mean FPA = 5.2 ng/mL before chemotherapy versus 8.3 ng/mL after chemotherapy, p less than 0.01) and were accompanied by an increase in the FPA generation rate. Infusion of heparin prior to chemotherapy significantly lowered plasma FPA levels and abolished post-chemotherapy FPA generation.
  
  
  CONCLUSIONS
  These data suggest that patients receiving chemotherapy express thrombin-like activity in plasma and, therefore, may be at risk for clinically significant intravascular activation of coagulation. Heparin diminished the laboratory evidence of this chemotherapy-related coagulopathy and may have a role in the prevention of thromboembolic disorders in some cancer patients undergoing cytotoxic therapy.
authors.affiliation: Veterans Administration Medical Center, Newington, Connecticut.
authors.forename: R L
authors.initials: RL
authors.lastname: Edwards
authors.forename: M
authors.initials: M
authors.lastname: Klaus
authors.forename: E
authors.initials: E
authors.lastname: Matthews
authors.forename: C
authors.initials: C
authors.lastname: McCullen
authors.forename: R D
authors.initials: RD
authors.lastname: Bona
authors.forename: F R
authors.initials: FR
authors.lastname: Rickles
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology; D005340:Fibrinogen / Q000378:metabolism*; D005344:Fibrinopeptide A / Q000378:metabolism*; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy; D010314:Partial Thromboplastin Time
chemical_list: D000970:Antineoplastic Agents; D005344:Fibrinopeptide A; D005340:Fibrinogen; D006493:Heparin